Shai Shmuel Erlich

20110178157, Jul 21, 2011

Dec 8, 2010

12/963600

Xiaomei Jin - Oceanside CA, US
Lei Yu - Oceanside CA, US
Hirokazu Takahashi - Sapporo, JP
Yasunobu Tanaka - Sapporo, JP
Yoshiro Niitsu - Sapporo, JP
Elena Feinstein - Rehovot, IL
Sharon Avkin-Nachum - Nes Ziona, IL
Hagar Kalinski - Rishon Le-Zion, IL
Igor Mett - Rehovot, IL
Shai Erlich - Belmont CA, US
Elizabeth C. Squiers - Half Moon Bay CA, US

A61K 31/713
C07H 21/02
A61P 43/00
C07H 21/00

514 44 A, 536 245

Provided herein are compositions, methods and kits for modulating expression of target genes, particularly heat shock protein 47 (hsp47). The compositions, methods and kits may include nucleic acid molecules (for example, short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA) or short hairpin RNA (shRNA)) that modulate a gene encoding hsp47, for example, the gene encoding human hsp47. The composition and methods disclosed herein may also be used in treating conditions and disorders associated with hsp47 such as liver fibrosis, pulmonary fibrosis, peritoneal fibrosis and kidney fibrosis.

20120141378, Jun 7, 2012

Jun 7, 2010

13/376766

Elena Feinstein - Rehovot, IL
Svetlana Adamsky - Gedera, IL
Shai Erlich - Belmont CA, US
Bruce Molitoris - Indianapolis IN, US

A61K 31/713
A61K 49/00
A61P 13/12

424 91, 514 44 A

The present invention relates to methods for treating chronic kidney disease (CKD) including methods for preventing or delaying onset of CKD and methods for preventing exacerbation and progression of CKD. In particular embodiments, the invention provides methods for treating a subject at risk of developing CKD comprising administering to the subject a composition comprising a) a therapeutically effective amount of at least one oligonucleotide compound which inhibits the expression of a human target gene associated with the kidney disease; and b) a pharmaceutically acceptable excipient or carrier, or mixtures thereof, thereby reducing the risk of CKD in the subject.

20180305696, Oct 25, 2018

Dec 5, 2017

15/832334

- Fremont CA, US
Shai Erlich - Concord CA, US
Daniel Rothenstein - Ramat Hasharon, IL
Nir Sharon - Jerusalem, IL
Daniel J. Odenheimer - Potomac MD, US
Elena Feinstein - Rehovot, IL

C12N 15/113
A61K 45/06
A61K 9/00
A61K 31/713

The invention, in some embodiments, relates to compounds and methods for the prevention of ischemia reperfusion injury (IRI) in organs, and in particular to IRI in organs aged 35 years and older. Specific uses include prevention of IRI in native organs in vivo, in reimplantations and in transplantations of donor organs aged 35 years and older. Additional embodiments include the prophylaxis of delayed graft function (DGF) and reduction in the frequency, amount and duration of dialysis in recipients of deceased donor kidney transplantations. The methods entail contacting the organ in vivo or ex vivo with a temporary p53 inhibitor. Novel temporary dsNA p53 inhibitors are further provided.

20170335327, Nov 23, 2017

Jul 14, 2017

15/650297

- Fremont CA, US
Shai Erlich - Concord CA, US
Daniel Rothenstein - Ramat Hasharon, IL
Nir Sharon - Jerusalem, IL
Daniel J. Odenheimer - Potomac MD, US
Elena Feinstein - Rehovot, IL

C12N 15/113
A61K 45/06
A61K 9/00
A61K 31/713

The invention, in some embodiments, relates to compounds and methods for the prevention of ischemia reperfusion injury (IRI) in organs, and in particular to IRI in organs aged 35 years and older. Specific uses include prevention of IRI in native organs in vivo, in reimplantations and in transplantations of donor organs aged 35 years and older. Additional embodiments include the prophylaxis of delayed graft function (DGF) and reduction in the frequency, amount and duration of dialysis in recipients of deceased donor kidney transplantations. The methods entail contacting the organ in vivo or ex vivo with a temporary p53 inhibitor. Novel temporary dsNA p53 inhibitors are further provided.

20170081665, Mar 23, 2017

May 27, 2015

15/312425

- Fremont CA, US
Shai Erlich - Concord CA, US
Daniel Rothenstein - Ramat Hasharon, IL
Nir Sharon - Jerusalem, IL
Daniel J. Odenheimer - Potomac MD, US
Elena Feinstein - Rehovot, IL

Quark Pharmaceuticals, Inc. - Fremont CA

C12N 15/113
A61K 9/00
A61K 31/713
A61K 45/06

The invention, in some embodiments, relates to compounds and methods for the prevention of ischemia reperfusion injury (IRI) in organs, and in particular to IRI in organs aged 35 years and older. Specific uses include prevention of IRI in native organs in vivo, in reimplantations and in transplantations of donor organs aged 35 years and older. Additional embodiments include the prophylaxis of delayed graft function (DGF) and reduction in the frequency, amount and duration of dialysis in recipients of deceased donor kidney transplantations. The methods entail contacting the organ in vivo or ex vivo with a temporary p53 inhibitor. Novel temporary dsNA p53 inhibitors are further provided.

20160108399, Apr 21, 2016

Oct 27, 2015

14/924284

- Osaka, JP
Lei YU - Oceanside CA, US
Hirokazu TAKAHASHI - Sapporo, JP
Yasunobu TANAKA - Sapporo, JP
Yoshiro NIITSU - Sapporo, JP
Elena FEINSTEIN - Rehovot, IL
Sharon AVKIN-NACHUM - Nes Ziona, IL
Hagar KALINSKI - Rishon Le-Zion, IL
Igor METT - Rehovot, IL
Shai ERLICH - Belmont CA, US
Elizabeth C. SQUIERS - Half Moon Bay CA, US
Ning CHEN - Pittsburgh PA, US

NITTO DENKO CORPORATION - Osaka

C12N 15/113

Provided herein are compositions, methods and kits for modulating expression of target genes, particularly heat shock protein 47 (hsp47). The compositions, methods and kits may include nucleic acid molecules (for example, short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA) or short hairpin RNA (shRNA)) that modulate a gene encoding hsp47, for example, the gene encoding human hsp47. The composition and methods disclosed herein may also be used in treating conditions and disorders associated with hsp47 such as liver fibrosis, pulmonary fibrosis, peritoneal fibrosis and kidney fibrosis.

20140235695, Aug 21, 2014

Mar 18, 2014

14/218422

- , unknown
Lei YU - Oceanside CA, US
Hirokazu TAKAHASHI - Sapporo, JP
Yasunobu TANAKA - Sapporo, JP
Yoshiro NIITSU - Sapporo, JP
Elena FEINSTEIN - Rehovot, IL
Sharon AVKIN-NACHUM - Nes Ziona, IL
Hagar KALINSKI - Rishon Le-Zion, IL
Igor METT - Rehovot, IL
Shai ERLICH - Belmont CA, US
Elizabeth C SQUIERS - Half Moon Bay CA, US
Ning CHEN - Pittsburgh PA, US

C12N 15/113

514 44 A, 536 245

Provided herein are compositions, methods and kits for modulating expression of target genes, particularly heat shock protein 47 (hsp47). The compositions, methods and kits may include nucleic acid molecules (for example, short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA) or short hairpin RNA (shRNA)) that modulate a gene encoding hsp47, for example, the gene encoding human hsp47. The composition and methods disclosed herein may also be used in treating conditions and disorders associated with hsp47 such as liver fibrosis, pulmonary fibrosis, peritoneal fibrosis and kidney fibrosis.

20140140922, May 22, 2014

Jan 27, 2014

14/165249

Elena Feinstein - Rehovot, IL
Svetlana Adamsky - Gedera, IL
Shai Erlich - Belmont CA, US
Bruce Molitoris - Indianapolis IN, US

QUARK PHARMACEUTICALS, INC. - Fremont CA

C12N 15/113

424 111, 514 44 A, 536 245

The present invention relates to methods for treating chronic kidney disease (CKD) including methods for preventing or delaying onset of CKD and methods for preventing exacerbation and progression of CKD. In particular embodiments, the invention provides methods for treating a subject at risk of developing CKD comprising administering to the subject a composition comprising a) a therapeutically effective amount of at least one oligonucleotide compound which inhibits the expression of a human target gene associated with the kidney disease; and b) a pharmaceutically acceptable excipient or carrier, or mixtures thereof, thereby reducing the risk of CKD in the subject.